The Florida Society of Clinical Oncology (FLASCO) hosted the 2018 FLASCO Fall Session, November 8th-10th, in Orlando, Florida at the Orlando World Center Marriott with approximately 450 attendees. More than 30 Florida Cancer Specialists (FCS) physicians and staff were in attendance, in addition to numerous FCS FLASCO Board Members and Liaisons.
Florida Cancer Specialists physician and 2017-2018 FLASCO Fall Session Program Committee Co-Chair, Dr. Eric Harris, moderated the General Session on “Precision Medicine” Saturday, November 9th, 2018. Dr. Harris, who practices at the Daytona Cancer Center in Daytona Beach, stated, “It is truly an honor to continue to serve this prestigious organization. FLASCO has long been one of the premiere professional oncology organizations in the state and it has distinguished itself as a catalyst to develop partnerships, share knowledge, and bring together physicians, staff members and other professionals to demonstrate strength and determination as we move forward in oncology.”
FCS CEO, Brad Prechtl, MBA, said, “Florida Cancer Specialists is proud to lend our support and leadership to FLASCO. One of the most effective ways to advance the field of oncology is to share knowledge and that’s exactly what FLASCO does. Our physicians and staff look forward to participating in this conference each year because it provides a great opportunity to learn from each other.”
FCS President & Managing Physician, Dr. Lucio Gordan, added, “As a community oncology practice, we rely on FLASCO to provide educational opportunities, advocacy and leadership for oncologists and allied health professionals throughout Florida. I am honored to say that FCS has such a prominent presence within leadership and events for FLASCO!”
FLASCO Executive Director, Dorothy Green, stated, “As the Executive Director of FLASCO I witness firsthand how much time and dedication the FCS Physicians and staff place into our organization – we are very grateful for the continued support year after year!”
- FCS Physician, Dr. Eric Harris | 2017 – 2018 Program Committee Co-Chair
- FCS Physician, Dr. Eric Harris, moderated General Session “Precision Medicine” CE
- FCS Director of Pharmacy, Ray Bailey, RPh moderated Pharmacy Track “Oral Oncolytics” session
- FCS Director of Research, Katie Goodman, RN, BSN, CCRP moderated Nursing/Patient Navigator Track “Navigating Patients: Understanding Clinical Trials”
- FCS Chief Revenue Cycle Officer, Sarah Cevallos, moderated Administrator Track “Prior Authorizations”
- FCS Physician, Maen Hussein, MD | Panelist
View photos from the 2018 FLASCO Fall Session here.
About Florida Cancer Specialists & Research Institute, LLC
Founded in 1984, Florida Cancer Specialists & Research Institute (FCS) is the largest independent medical oncology/hematology practice in the United States. With more than 220 physicians, 200 advanced practice registered nurses (APRN) and physician assistants (PA) and nearly 100 locations in our network, we are committed to providing world-class cancer care in community-based settings close to home.
Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, FCS offers patients access to more clinical trials than any private oncology practice in Florida. In the past 3 years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.* Our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report. Trained in such prestigious medical schools and research institutes as Duke, Stanford, Harvard, Emory, M.D. Anderson, and Memorial Sloan-Kettering, the physicians of Florida Cancer Specialists provide leadership and consultation in the state’s leading hospitals.
FCS serves patients on the Gulf Coast from Naples to the greater Tampa Bay area, north as far as Tallahassee, in Orlando and surrounding Central Florida communities, and on the East Coast from Palm Beach County to the Jacksonville area.
Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research and cutting-edge technologies that help advance targeted treatments and genetically-based immunotherapies, and embodied by our outstanding team of highly-trained and dedicated physicians, clinicians and staff.
* Prior to approval